Review article: prevention of postsurgical relapse and recurrence in Crohn's disease.
After first resection in Crohn's disease at 1 year 60-80% of patients have endoscopic recurrence, 10-20% have clinical relapse, and 5% have surgical recurrence.1, 2 This review focuses on the actual evidence on the prevention of recurrence and relapse dealing with risk factors and with drugs. Smoking is the only risk factor for Crohn's disease, that has been shown to be related to both endoscopic and surgical recurrence and relapse. Among the different drugs evaluated, some (Mesalamine and Metronidazole) have been shown to be effective, whereas others (immunosuppressive) need to be evaluated in further, new trials.
Cottone
M
M
Clinica Medica R Università di Palermo, Cattedra di Gastroenterologia Roma, CNR Palermo, Italy. dickens@tin.it
Orlando
A
A
Viscido
A
A
Calabrese
E
E
Cammà
C
C
Casà
A
A
D000890:Anti-Infective Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D019819:Budesonide / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D019804:Mesalamine / Q000627:therapeutic use; D008795:Metronidazole / Q000627:therapeutic use; D009950:Ornidazole / Q000627:therapeutic use; D019936:Probiotics / Q000627:therapeutic use; D012307:Risk Factors; D055502:Secondary Prevention; D012907:Smoking / Q000009:adverse effects
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D008795:Metronidazole; D019804:Mesalamine; D019819:Budesonide; D009950:Ornidazole